| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
MRC Environmental Epidemiology Unit, Southampton General Hospital, United Kingdom.
OBJECTIVE--To identify the risk of hip fracture in patients with rheumatoid arthritis and those taking corticosteroids. METHODS--In a population based case-control study, we compared 300 consecutive patients with hip fracture aged 50 years and over from a defined district and 600 age and sex matched community controls. RESULTS--The risk of hip fracture was increased in patients with rheumatoid arthritis (odds ratio (OR) 2.1; 95% confidence interval (CI) 1.0 to 4.7) and those receiving corticosteroids (OR 2.7; 95% CI 1.2 to 5.8). The risk attributable to rheumatoid arthritis was markedly reduced by adjusting for functional impairment, while that for steroid use remained after adjusting for body mass index, smoking, alcohol, and functional status. CONCLUSIONS--Hip fracture risk is approximately doubled amongst patients with rheumatoid arthritis and among those taking steroids. These risk increases are, to some extent, independent of each other. In rheumatoid arthritis, the risk was most closely associated with functional impairment, whereas steroid use did not appear to be confounded by this variable.
This article has been cited by other articles:
|
|
 |
|
  M Guler-Yuksel, J Bijsterbosch, Y P M Goekoop-Ruiterman, J K de Vries-Bouwstra, H M J Hulsmans, W M de Beus, K H Han, F C Breedveld, B A C Dijkmans, C F Allaart, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis Ann Rheum Dis, June 1, 2008; 67(6): 823 - 828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Guler-Yuksel, J Bijsterbosch, Y P M Goekoop-Ruiterman, F C Breedveld, C F Allaart, J K de Vries-Bouwstra, B A C Dijkmans, W F Lems, H K Ronday, A J Peeters, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(11): 1508 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Saviola, L. Abdi. Ali, S. Shams. Eddin, A. Coppini, F. Cavalieri, L. Campostrini, S. Sacco, M. Bucci, G. Cirino, and M. Rossini Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study Rheumatology, June 1, 2007; 46(6): 994 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. P. van Staa, P. Geusens, B. Zhang, H. G. M. Leufkens, A. Boonen, and C. Cooper Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids Rheumatology, March 1, 2007; 46(3): 460 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.I. Syed, N.A. Patel, S. Jan, A. Shaikh, B. Grunden, and K. Morar Symptomatic refractures after vertebroplasty in patients with steroid-induced osteoporosis. AJNR Am. J. Neuroradiol., October 1, 2006; 27(9): 1938 - 1943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. T. Summey and G. Yosipovitch Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update Arch Dermatol, January 1, 2006; 142(1): 82 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Armstrong, C M Swarbrick, S R Pye, and T W O'Neill Occurrence and risk factors for falls in rheumatoid arthritis Ann Rheum Dis, November 1, 2005; 64(11): 1602 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhattacharya, M. Rahman, J. Banu, R. A. Lawrence, H. S. McGuff, I.R. Garrett, M. Fischbach, and G. Fernandes Inhibition of Osteoporosis in Autoimmune Disease Prone MRL/Mpj-Faslpr Mice by N-3 Fatty Acids J. Am. Coll. Nutr., June 1, 2005; 24(3): 200 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T.-P. van Staa, P. Geusens, H.A.P. Pols, C. de Laet, H.G.M. Leufkens, and C. Cooper A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids QJM, March 1, 2005; 98(3): 191 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M C Lodder, Z de Jong, P J Kostense, E T H Molenaar, K Staal, A E Voskuyl, J M W Hazes, B A C Dijkmans, and W F Lems Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density Ann Rheum Dis, December 1, 2004; 63(12): 1576 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kaz Kaz, D. Johnson, S. Kerry, U. Chinappen, K. Tweed, and S. Patel Fall-related risk factors and osteoporosis in women with rheumatoid arthritis Rheumatology, October 1, 2004; 43(10): 1267 - 1271. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Gluck and G. Colice Recognizing and Treating Glucocorticoid-Induced Osteoporosis in Patients With Pulmonary Diseases Chest, May 1, 2004; 125(5): 1859 - 1876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R E Orstavik, G Haugeberg, T Uhlig, P Mowinckel, J A Falch, J I Halse, and T K Kvien Self reported non-vertebral fractures in rheumatoid arthritis and population based controls: incidence and relationship with bone mineral density and clinical variables Ann Rheum Dis, February 1, 2004; 63(2): 177 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J W J Bijlsma, M Boers, K G Saag, and D E Furst Glucocorticoids in the treatment of early and late RA Ann Rheum Dis, November 1, 2003; 62(11): 1033 - 1037. [Full Text] [PDF]
|
|
|
|
|
|
N. Porter, H.L. Beynon, and H.S. Randeva Endocrine and reproductive manifestations of sarcoidosis QJM, August 1, 2003; 96(8): 553 - 561. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Ringe, A. Dorst, H. Faber, K. Ibach, and J. Preuss Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis Rheumatology, June 1, 2003; 42(6): 743 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I W Chantler, M W J Davie, S F Evans, and J S Rees Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service Ann Rheum Dis, April 1, 2003; 62(4): 350 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hirayama, L. Danks, A. Sabokbar, and N. A. Athanasou Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis Rheumatology, November 1, 2002; 41(11): 1232 - 1239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Yeap and D. J. Hosking Management of corticosteroid-induced osteoporosis Rheumatology, October 1, 2002; 41(10): 1088 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S P Tuck and R M Francis Osteoporosis Postgrad. Med. J., September 1, 2002; 78(923): 526 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M Nolla, J Fiter, C Gomez-Vaquero, J J Alegre, J Valverde, and D Roig-Escofet Value of clinical factors in selecting postmenopausal women with rheumatoid arthritis for bone densitometry Ann Rheum Dis, August 1, 2001; 60(8): 799 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Yood, L. R. Harrold, L. Fish, J. Cernieux, S. Emani, E. Conboy, and J. H. Gurwitz Prevention of Glucocorticoid-Induced Osteoporosis: Experience in a Managed Care Setting Arch Intern Med, May 28, 2001; 161(10): 1322 - 1327. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T M Huusko, M Korpela, P Karppi, V Avikainen, H Kautiainen, and R Sulkava Threefold increased risk of hip fractures with rheumatoid arthritis in Central Finland Ann Rheum Dis, May 1, 2001; 60(5): 521 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L J Walsh, C A Wong, J Oborne, S Cooper, S A Lewis, M Pringle, R Hubbard, and A E Tattersfield Adverse effects of oral corticosteroids in relation to dose in patients with lung disease Thorax, April 1, 2001; 56(4): 279 - 284. [Abstract] [Full Text]
|
|
|
|
 |
|
 D Sen and R W Keen Osteoporosis in systemic lupus erythematosus: prevention and treatment Lupus, March 1, 2001; 10(3): 227 - 232. [Abstract] [PDF]
|
|
|
|
|
|
T. P. van Staa, H. G. M. Leufkens, L. Abenhaim, B. Zhang, and C. Cooper Oral corticosteroids and fracture risk: relationship to daily and cumulative doses Rheumatology, December 1, 2000; 39(12): 1383 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.M. Francis, S.P. Baillie, A.J. Chuck, P.R. Crook, T. Daymond, N. Dunn, J.N. Fordham, C. Kelly, and A. Rodgers Management of osteoporosis in patients with hip fractures QJM, August 1, 2000; 93(8): 501 - 506. [Full Text] [PDF]
|
|
|
|
|
|
M. Conron, C. Young, and H. L. C. Beynon Calcium metabolism in sarcoidosis and its clinical implications Rheumatology, July 1, 2000; 39(7): 707 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M NOLLA, C GÓMEZ-VAQUERO, J FITER, and D ROIG-ESCOFET Computed digital absorptiometry of the hand: screening method of bone loss in postmenopausal women with RA Ann Rheum Dis, June 1, 2000; 59(6): 490b - 490. [Full Text]
|
|
|
|
 |
|
 M E LLOYD, T D SPECTOR, and R HOWARD Osteoporosis in neurological disorders J. Neurol. Neurosurg. Psychiatry, May 1, 2000; 68(5): 543 - 547. [Full Text]
|
|
|
|
|
|
A. Struijs, A. Smals, S. A. de Witte, W. H. L. Hackeng, and H. Mulder Acute effects of etidronate on glucocorticoid-induced bone degradation Rheumatology, May 1, 2000; 39(5): 523 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.P. van Staa, H.G.M. Leufkens, L. Abenhaim, B. Begaud, B. Zhang, and C. Cooper Use of oral corticosteroids in the United Kingdom QJM, February 1, 2000; 93(2): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. R. Reid Glucocorticoid Osteoporosis: Reid IR Glucocorticoid osteoporosis J Intensive Care Med 1999, 14231-242 J Intensive Care Med, September 1, 1999; 14(5): 231 - 242. [PDF]
|
|
|
|
 |
|
 J E COMPSTON Management of bone disease in patients on long term glucocorticoid therapy Gut, June 1, 1999; 44(6): 770 - 772. [Full Text] [PDF]
|
|
|
|
|
|
P. Geusens, J. Dequeker, J. Vanhoof, R. Stalmans, S. Boonen, J. Joly, J. Nijs, and J. Raus Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study Ann Rheum Dis, December 1, 1998; 57(12): 724 - 727. [Abstract] [Full Text]
|
|
|
|
|
|
W F LEMS and B A C DIJKMANS Should we look for osteoporosis in patients with rheumatoid arthritis? Ann Rheum Dis, June 1, 1998; 57(6): 325 - 327. [Full Text]
|
|
|
|
|
|
S. COWAN, S. MORIN, and P. ERNST Bisphosphonates and glucocorticoid-induced osteoporosis: implications for patients with respiratory diseases Thorax, May 1, 1998; 53(5): 331 - 332. [Full Text]
|
|
|
|
 |
|
 C. Roux, P. Oriente, R. Laan, R. A. Hughes, J. Ittner, S. Goemaere, O. Di Munno, J. M. Pouillès, S. Horlait, and B. Cortet Randomized Trial of Effect of Cyclical Etidronate in the Prevention of Corticosteroid-Induced Bone Loss J. Clin. Endocrinol. Metab., April 1, 1998; 83(4): 1128 - 1133. [Abstract] [Full Text]
|
|
|
|
|
|
J. W J BIJLSMA Prevention of glucocorticoid induced osteoporosis Ann Rheum Dis, September 1, 1997; 56(9): 507 - 509. [Full Text]
|
|
|
|
 |
|
 C. Olesen, H. T. Sorensen, F. H. Steffensen, G. L. Nielsen, and J. Olsen Danish data confirm low prevalence of HRT among women prescribed oral corticosteroids BMJ, November 16, 1996; 313(7067): 1264 - 1264. [Full Text]
|
|
|
|
 |
|
 Corticosteroid-induced osteoporosis DTB, November 1, 1996; 34(11): 84 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L J Walsh, C A Wong, M Pringle, and A E Tattersfield Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study BMJ, August 10, 1996; 313(7053): 344 - 346. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
